
Vascular Pharmacology 55 (2011) 17–25

Contents lists available at ScienceDirect

**Vascular Pharmacology**

journal homepage: www.elsevier.com/locate/vph

---

### Review

#### The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function

**Matthias R. Meyer** ${}^{a,b}$, **Eric R. Prossnitz** ${}^{b}$, **Matthias Barton** ${}^{a,*}$

${}^{a}$ Molecular Internal Medicine, University of Zurich, Zurich, Switzerland  
${}^{b}$ Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM, United States

---

#### ARTICLE INFO

**Article history:**  
Received 10 February 2011  
Received in revised form 19 June 2011  
Accepted 25 June 2011  

**Keywords:**  
Blood pressure  
Endothelium  
Menopause  
Nitric oxide  
Vasodilation  

---

#### ABSTRACT

Endogenous estrogens are important regulators of cardiovascular homeostasis in premenopausal women and delay the development of hypertension and coronary artery disease. These hormones act via three different estrogen receptors affecting both gene transcription and rapid signaling pathways in a complex interplay. In addition to the classical estrogen receptors ERα and ERβ, which are known mediators of estrogen-dependent vascular effects, a G protein-coupled estrogen receptor termed GPER that is expressed in the cardiovascular system has recently been identified. Endogenous human 17β-estradiol, selective estrogen receptor modulators (SERMs) including tamoxifen and raloxifene, and selective estrogen receptor downregulators (SERDs) such as ICI 182,780 are all agonists of GPER, which has been implicated in the regulation of vasomotor tone and protection from myocardial ischemia/reperfusion injury. As a result, understanding the individual role of ERα, ERβ, and GPER in cardiovascular function has become increasingly complex. With accumulating evidence that GPER is responsible for a variety of beneficial cardiovascular effects of estrogens, this receptor may represent a novel target to develop effective strategies for the treatment of cardiovascular diseases by tissue-specific, selective activation of estrogen-dependent molecular pathways devoid of side effects seen with conventional hormone therapy.

© 2011 Elsevier Inc. All rights reserved.

---

#### Contents

1. Estrogen receptors and vascular estrogen signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Barton and Meyer, 2009) and have been linked to a higher risk of cardiovascular diseases such as myocardial infarction, stroke, and congestive heart failure (Vasan et al., 2001). In line with these epidemiological data, a variety of beneficial cardiovascular effects of endogenous estrogens are known based on numerous experimental studies, including vasodilator activity and improvement of ischemia/reperfusion-related myocardial injury (Deschamps et al., 2010; Meyer et al., 2006; Meyer and Barton, 2009). Conversely, randomized clinical trials using conjugated equine estrogens and medroxyprogesterone acetate for postmenopausal hormone therapy could not recapitulate these beneficial effects but reported increased cardiovascular risk instead (Hulley et al., 1998; Rossouw et al., 2002), indicating that this treatment is not suitable for primary or secondary prevention of cardiovascular diseases.

The controversial outcome of these trials may partly result from the complexity of vascular estrogen signaling (Fig. 1), which involves at least three different estrogen receptors. Estrogen receptor α (ERα) was identified in the 1960's (then termed ER) (Soloff and Szego, 1969). In 1996, the less characterized estrogen receptor β (ERβ) was found (Kuiper et al., 1996). ERα and ERβ largely function as transcriptional regulators, but a small fraction may also be present at the plasma membrane, where estrogen binding activates intracellular signaling pathways that mediate acute effects of estrogens, such as rapid vasodilation (Meyer et al., 2006, 2009). In 1997, a third ER, the seven-transmembrane G protein-coupled ER termed GPR30, was cloned from shear-stress exposed human endothelial cells among other sources (Takada et al., 1997). More recently, GPR30 has been shown to activate rapid signaling cascades, such as extracellular signal-related kinase (ERK) and phosphatidylinositol-3-kinase (PI₃K), after estrogen binding (Filardo et al., 2000; Revankar et al., 2005; Thomas et al., 2005). After establishing GPR30 as a *bona fide* estrogen-binding receptor, it was renamed GPER by the International Union of Basic and Clinical Pharmacology (Alexander et al., 2008). Similar to ERα and ERβ (Meyer et al., 2006), GPER is expressed throughout the cardiovascular system in humans and animals of both sexes (Bopassa et al., 2010; Broughton et al., 2010; Deschamps and Murphy, 2009; Ding et al., 2009; Filice et al., 2009; Haas et al., 2007, 2009; Isensee et al., 2009; Lindsey et al., 2009; Ma et al., 2010; Takada et al., 1997). This suggests that in addition to ERα and ERβ, GPER also plays a physiological role in regulation of vascular and myocardial function. With the identification of three different receptors capable of mediating vascular estrogen signaling, the understanding of the cardiovascular effects of estrogen has become increasingly complex. This review addresses the individual role of the different ERs in cardiovascular function with a particular focus on its newest member, GPER.

## 2. Ligands of vascular estrogen receptors

Although a variety of natural and synthetic estrogens are able to induce effects on the cardiovascular system, it is important to separate their ability to regulate ERα, ERβ, and GPER activity. 17β-Estradiol, the major human estrogen lost after menopause, is a combined activator of ERα, ERβ, and GPER, and mediates numerous beneficial vascular effects. Although 17β-estradiol is primarily synthesized by the ovaries, the enzyme aromatase converts androgens into 17β-estradiol and estrone at many sites throughout the body including the vascular wall, where they may have specialized local effects (Harada et al., 1999). Estrone and other endogenous estrogen-based steroids display a low binding affinity for ERα, ERβ, and GPER at physiological concentrations, and their physiological actions are less clear (Kuiper et al., 1998; Revankar et al., 2005; Thomas et al., 2005). Furthermore, humans are exposed to a variety of environmental and man-made estrogenic compounds at low levels (Jacobs and Lewis, 2002). Natural environmental estrogens are synthesized by plants (phytoestrogens) and include coumestans and isoflavones, whereas synthetic estrogenic compounds (xenoestrogens, known as endocrine disruptors) comprise chemical detergents, pesticides, and plastic monomers. In fact, the isoflavone genistein is able to induce vasodilation (Martin et al., 2008), and has now been shown to not only activate ERα and ERβ, but also GPER (Thomas and Dong, 2006). Some xenoestrogens such as nonylphenol and DDT have also been implicated in regulation of vascular function (Hsieh et al., 2009; Ruehlmann et al., 1998), and these compounds weakly bind ERα/ERβ, but are also agonists of GPER (Thomas and Dong, 2006). Taken together, numerous endogenous and exogenous estrogenic compounds implicated in cardiovascular physiology are now known to activate all three known estrogen receptors.

Research to improve successful treatment of estrogen-sensitive tumors, breast cancer in particular, led to the development of drugs that oppose the action of estrogen. Referred to as selective estrogen receptor downregulators (SERDs), compounds such as ICI 182,780 (fulvestrant) abolish ERα/ERβ signaling in all tissues (Shanle and Xu, 2010). However, a group of compounds known as selective estrogen receptor modulators (SERMs) do not uniformly act as estrogen antagonists, but are generally regarded as ER agonists in the cardiovascular system, bone, and liver, and as ER antagonists in breast tissue (Katzenellenbogen and Katzenellenbogen, 2002). Importantly, the SERM tamoxifen as well as the SERD ICI 182,780 do not solely interact with ERα and ERβ; they also display significant binding to GPER (Thomas et al., 2005) and induce GPER-dependent signaling in breast cancer cell lines (Filardo et al., 2000; Revankar et al., 2005). Their role as GPER agonists has been confirmed in several other cell types and tissues (Prossnitz and Barton, 2009), indicating that this receptor mediates estrogenic effects even in the presence of concomitant blockade of ERα and ERβ. This also indicates that older studies

**Fig. 1.** Proposed estrogen receptor (ER)-activated signaling pathways involved in vasodilation. 17β-Estradiol (E₂) can activate a subpopulation of ER at the plasma membrane (mER) that interacts with adaptor proteins (adaptor) and signaling molecules such as c-Src (1), which is critical for downstream ER-induced signaling via PI₃K/Akt and MAPK pathways. E₂ also binds to the G protein-coupled estrogen receptor GPER, which is primarily localized to the endoplasmic reticulum (2). GPER activates downstream effectors, such as adenylate cyclase (resulting in cAMP production), and c-Src. c-Src, in turn, activates matrix metalloproteinases (MMP), which cleave pro-heparin-bound-epidermal growth factor receptors (EGFR). EGFR leads to multiple downstream events, including activation of MAPK and PI₃K. Once activated, PI₃K can induce NO generation by NO synthase (NOS) in vascular endothelial (eNOS) or smooth muscle cells (nNOS). Membrane-permeant NO, in turn, activates guanylate cyclase (resulting in cGMP production). The NO/cGMP pathway is involved in acute vasodilator mechanisms, such as protein kinase G (PKG)-dependent regulation of myosin light chain phosphorylation, and activation of large-conductance calcium-activated potassium (BKCa) channels. E₂ also regulates cellular gene expression either via binding of ER dimers in the promoter region of target genes (3), through interaction of ER with other classes of transcription factors (TF) (4), or by regulation of TF phosphorylation (5). Target genes regulating vascular homeostasis include NOS and inflammatory cytokines. Adapted from Mol Cell Endocrinol, Vol. 308, Meyer, M.R., Haas, E., Prossnitz, E.R., Barton M, Non-genomic regulation of vascular cell function and growth by estrogen, Pages 9–16, ©2009, with permission from Elsevier.

investigating cardiovascular effects of SERMs and SERDs may in fact point at GPER-dependent effects.

As GPER is known to bind many of the same ligands as ERα and ERβ (Fig. 2), selective agonists/antagonists were needed to unravel the functional roles of the individual receptors, particularly GPER. This led to the identification of the first GPER-specific agonist G-1 (Bologna et al., 2006) and the first GPER-selective antagonist G15 (Dennis et al., 2009). Both compounds share a tetrahydro-3H-cyclopenta-[c] quinoline scaffold domain and show an extremely high selectivity for GPER over ERα and ERβ. In addition, agonists for ERα (PPT) and ERβ (DPN) (Harrington et al., 2003) have been used in the past years. The availability of these compounds has provided the opportunity to better characterize the role of individual ERs, and GPER in particular, in cardiovascular physiology.

## 3. Mechanisms of estrogen-dependent vasodilation

17β-Estradiol is a powerful vasodilator of human blood vessels (Mügge et al., 1993; Silva de Sa and Meirelles, 1977), and acute effects on vasomotor tone have been observed in arteries of both women and men (Haas et al., 2007; Mügge et al., 1993). Shortly after the seminal observation that endothelial cells release a relaxing factor in response to acetylcholine (Furchgott and Zawadzki, 1980) and its subsequent identification as nitric oxide (NO) (Furchgott, 1988; Ignarro et al., 1987), enhanced endothelium-dependent responses to acetylcholine were reported in estrogen-treated ovariectomized animals (Gisclard et al., 1988). Similarly, flow-mediated vasodilation and NO production correlate with high estrogen levels during the menstrual cycle and increase after estrogen therapy in postmenopausal women (Miller and Duckles, 2008). These findings support the notion that estrogen acutely and chronically enhances endothelium-/NO-dependent relaxation of human arteries, including human coronary arteries (Barton et al., 1998; Miller and Duckles, 2008). Estrogen-stimulated endothelium-dependent NO release is the result of rapid PI3K/Akt activation and subsequent phosphorylation of endothelial (type III) NO synthase (eNOS) (Haynes et al., 2000; Simoncini et al., 2000), although other mechanisms have also been proposed (Chow et al., 2010). This effect is believed to be mediated by subpopulations of ERα and possibly ERβ that localize to vesicular invaginations of the plasma membrane termed caveolae (Fig. 1) (Chambliss et al., 2000, 2002; Simoncini et al., 2000). However, endothelium-dependent relaxation in response to estrogens does not involve NO exclusively, but is also mediated by endothelium-derived hyperpolarizing factors (EDHFs), including epoxyeicosatrienoic acids (EETs), H₂O₂, potassium, and endothelial gap junction communications

![Figure 2](#fig:2)

Fig. 2. Agonists and antagonists of GPER and plasma membrane-associated subpopulations of ERα and ERβ involved in rapid vascular estrogen signaling. Green/grey: activation, red/black arrows inhibition, and the orange arrow indicates tissue-dependent activation or inhibition. SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor downregulator.

(Huang et al., 2004; Luksha et al., 2006; Traupe et al., 2007). In addition, estrogens can act directly on vascular smooth muscle cells to regulate vascular function (White, 2002). These endothelium-independent effects include estrogen-dependent regulation of calcium and potassium fluxes (White, 2002), mainly through the activity of large-conductance calcium-and voltage-activated potassium (BKCa) channels (Fig. 1) (Han et al., 2007; White et al., 1995). Indeed, 17β-estradiol-dependent vasodilator responses in human coronary arteries remain effective after removal of endothelial cells (Mügge et al., 1993). Moreover, estrogen also indirectly reduces vasomotor tone by inhibiting the activity of vasoconstrictors, such as prostanoids, endothelin-1, and angiotensin I (Barton and Meyer, 2009; Mügge et al., 1997).

In addition to 17β-estradiol, an agonist of ERα, ERβ, and GPER, there has been a great interest in defining the role of SERMs in the regulation of vascular tone. Tamoxifen and raloxifene, which are agonists of GPER (Prossnitz and Barton, 2009), activate BKCa channels and evoke acute endothelium-independent vasodilation (Darkow et al., 1997; Hutchinson et al., 2001; Leung et al., 2007b). They also induce NO-mediated endothelium-dependent relaxation and increase eNOS phosphorylation in porcine coronary arteries and other vascular beds (Chan et al., 2010; Figtree et al., 1999; Leung et al., 2006, 2007a). Moreover, raloxifene activates eNOS via the PI3K/Akt-pathway in endothelial cells (Simoncini et al., 2002). Recently, the SERM estrogen-dendrimer conjugate was found to activate eNOS and stimulate growth of endothelial cells (Chambliss et al., 2010). On the other hand, the endogenous SERM and cholesterol metabolite 27-hydroxycholesterol decreases vascular NOS expression and activity (Umetani et al., 2007). Thus, both 17β-estradiol and several synthetically generated estrogen-like substances affect vascular function in distinct ways, although it is often unclear which ER mediates these responses. Defining the role of individual ERs in response to activation by SERMs may help to identify and selectively target ERs that mediate the beneficial vascular effects of estrogens.

## 4. Role of ERα and ERβ for vascular function

Estrogens acutely reduce vascular tone in various arteries of different species, yet the molecular mechanisms and the role of individual estrogen receptors in this response are less clear. Long-term 17β-estradiol treatment increases basal NO production in thoracic aorta of ERβ-, but not of ERα-knockout mice, indicating that ERα mediates NO-dependent vasodilation (Darblade et al., 2002). On the other hand, ERβ-knockout mice develop elevated blood pressure as they age, also suggesting a role for ERβ (Zhu et al., 2002). Indeed, disruption of ERβ abrogates the effect of estrogen to attenuate vasoconstriction (Zhu et al., 2002). Conversely, 17β-estradiol lacks vasodilatory effects in perfused carotid or femoral arteries of either ERα- or ERβ-knockout mice (Guo et al., 2005). In addition, 17β-estradiol stimulates neither ERK nor PI3K activity in carotid arteries of ERα- or ERβ-deficient animals (Guo et al., 2005). This is not only compatible with the notion that both ERα and ERβ are required for estrogen-dependent vasodilation, but also that other mechanisms independent of ERα/ERβ may be involved in these responses. Moreover, it is likely that a functional crosstalk between ERs defines the vasodilator effect of estrogens (Matthews and Gustafsson, 2003). In porcine coronary arteries, selective activation of ERα by PPT evokes a rapid, endothelium- and NO-dependent relaxant response within minutes, followed by a more sustained NO-independent relaxing effect (Traupe et al., 2007). In contrast, non-selective ER activation by 17β-estradiol and selective activation of ERβ by DPN causes a sustained relaxation only (Traupe et al., 2007). This points to an inhibitory role of ERβ on ERα-dependent, NO-mediated acute vasodilation. A similar effect has also been suggested in murine femoral arteries, where 17β-estradiol and PPT induce NO-dependent vasodilation only in animals lacking ERβ, but not in wild-type mice (Cruz et al., 2006). Of note, PPT- and DPN-dependent vasodilator effects

differ between distinct vascular beds and species (Al Zubair et al., 2005; Bolego et al., 2005). Taken together, functional interactions of both ERα and ERβ are likely to regulate vasomotor tone depending on anatomical localization of vascular beds in different species.

Conversely, a number of investigators found that the ERα/ERβ-antagonist (but GPER-agonist (Filardo et al., 2000; Thomas et al., 2005)) ICI 182,780 does not block estrogen-dependent vasodilator effects in several vascular beds of different species (Bracamonte et al., 2002; Scott et al., 2007; Shaw et al., 2000; Sudhir et al., 1995; Teoh et al., 1999). Moreover, we recently demonstrated that ICI 182,780 by itself causes rapid dilation in epicardial porcine coronary arteries, which represent a good model of the human coronary vasculature with regard to size and mediators of vascular function (Fig. 2B) (Meyer et al., 2010). These findings suggest that this vasodilator response does not depend on the activity of ERα and ERβ, but that these responses are mediated by GPER instead (Meyer et al., 2010). In line with these findings, ICI 182,780 causes a rapid, NO-dependent dilation of pressurized carotid (but not femoral) arteries of ovariectomized mice (Guo et al., 2005), and acts as a vasodilator in rat superior mesenteric arteries (Keung et al., 2011). Interestingly, vasodilator effects in response to ICI 182,780 are absent in carotid arteries of mice lacking ERα or ERβ (Guo et al., 2005), which would be compatible with crosstalk between GPER, ERα and ERβ recently suggested (Albanito et al., 2007; Gao et al., 2011). From a clinical point of view, vasodilator effects of ICI 182,780 (fulvestrant, Faslodex®) via GPER may provide the first mechanistic explanation for symptomatic hypotension, a common side effect of this agent when used as endocrine treatment for advanced breast cancer (Vergote and Abram, 2006).

## 5. GPER: a novel regulator of vascular tone and blood pressure

GPER is an intracellular transmembrane G protein-coupled receptor that mediates rapid estrogen signaling (Filardo et al., 2000; Revankar et al., 2005; Thomas et al., 2005). The potential relevance of GPER in cardiovascular physiology was perhaps first suggested by one of the approaches used to clone cDNA encoding GPER in human endothelial cells exposed to fluid shear stress (Takada et al., 1997). To better define the role of GPER in estrogen-dependent vasodilation, the selective GPER-agonist G-1 (Bologna et al., 2006) as well as genetically modified animals have been used. G-1 acutely dilates human internal mammary and porcine coronary arteries, rat aorta and mesenteric arteries, as well as rat and murine carotid arteries from males and females, with the effect being less potent in larger conduit arteries (Fig. 3) (Broughton et al., 2010; Haas et al., 2009; Lindsey et al., 2009, 2011; Meyer et al., 2010). In human internal mammary and murine carotid arteries, the G-1-dependent effect was more pronounced than that of 17β-estradiol, again suggesting that estrogen-dependent vasodilation involves complex functional crosstalk between GPER, ERα, and ERβ (Fig. 3A) (Haas et al., 2009). G-1 also inhibits endothelin- (Meyer et al., 2010), angiotensin II- (Lindsey et al., 2009), and serotonin-dependent (Haas et al., 2009) contractions in certain vascular beds. Interestingly, G-1 regulates calcium flux in vascular smooth muscle cells, an effect that is inhibited by GPER siRNA treatment (Haas et al., 2009). In fact, GPER activation by G-1 abrogates calcium flux induced by the vasoconstrictor serotonin indicating calcium-antagonistic or desensitizing effects, with intracellular application being much more rapid than extracellular application, indicative of the intracellular function of GPER (Haas et al., 2009).

Acute vasodilation in response to G-1 is abolished in animals lacking the GPER gene (Haas et al., 2009) or after pretreatment with the GPER-selective antagonist G15 (Lindsey et al., 2011), providing further evidence for a role of GPER for control of vasomotor tone (Fig. 3B). In GPER-deficient mice, development of hypertension in females at 9 months of age has been claimed; however, this as-

Fig. 3. GPER-dependent regulation of vascular tone. In precontracted carotid arteries from mice, the selective GPER-agonist G-1 (3 μM) causes acute dilation, which is even stronger than that of 17β-estradiol (E2, 3 μM, A). Dilatory effects of G-1 (3 μM) in carotid arteries of wild-type mice (GPER +/+) are absent in GPER-knockout animals (GPER −/−, B). Acute exposure to G-1 (3 μM) and the GPER agonist and ERα/ERβ antagonist ICI 182,780 (ICI, 3 μM) for 60 min evokes similar vasodilator responses of porcine epicardial coronary arteries (C). Intravenous injection of G-1 at increasing concentrations (4.12 ng/kg, 41.2 ng/kg, 412 ng/kg, and 20.6 μg/kg) acutely reduces mean arterial blood pressure (MAP) in normotensive rats. For comparison, the response to acetylcholine (ACh, 30 ng/kg) is shown (D). CTL, solvent control (ethanol 0.3%). Panels A, B, and D are reproduced from Haas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G.C., Gao, X., Mueller-Guerre, L., Marjon, N.A., Gut, A., Minotti, R., Meyer, M.R., Amann, K., Ammann, E., Perez-Dominguez, A., Genoni, M., Clegg, D.J., Dun, N.J., Resta, T.C., Prosnitz, E.R., Barton, M., Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity, Circ Res, 104(3), 288–291, ©2009 by the American Heart Association, with permission of the publisher. Panel C is adapted from Meyer, M.R., Baretella, O., Prosnitz, E.R., Barton, M., Dilatation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780, Pharmacology, 86(1), 58–64, ©2010, with permission from S. Karger AG, Basel, Switzerland.

sumption was based on blood pressure differences in wild-type mice, and mean blood pressure values were essentially normotensive in all groups investigated (Martensson et al., 2009). On the other hand, intravenous injection of G-1 in normotensive rats acutely reduces mean arterial blood pressure (Fig. 3D) (Haas et al., 2009). Moreover, treatment with G-1 for 2 weeks lowers blood pressure only in ovariectomized but not in ovary-intact female nor in male mRen2 Lewis rats, an estrogen-sensitive model of hypertension (Lindsey et al., 2009). In these animals, angiotensin II type 1 receptor and angiotensin-converting enzyme gene expression was reduced by G-1 treatment, suggesting that GPER activation lowers blood pressure in part by attenuating vascular angiotensin II signaling (Lindsey et al., 2009). In line with G-1-dependent effects on the renin-angiotensin-aldosterone system is a recent report suggesting that vascular signaling of aldosterone may involve GPER-dependent pathways (Gros et al., 2011). Taken together, these studies clearly indicate a role for GPER activation mediating acute and chronic vasodilation in response to estrogen (Table 1).

M.R. Meyer et al. / Vascular Pharmacology 55 (2011) 17–25

6. Mechanisms of GPER-dependent vasodilation

While several investigators have reported vasodilator effects of G-1, the mechanisms involved are still scarcely understood. In rat aorta, carotid and mesenteric as well as in porcine coronary arteries, G-1-mediated relaxation depends at least partly on the presence of an intact endothelium and is prevented by the NOS inhibitor L-NAME (Broughton et al., 2010; Lindsey et al., 2011; Meyer et al., 2010). This suggests that release of endothelium-derived NO is involved in GPER-dependent vasodilation in certain vascular beds. However, the exact functional and molecular interactions of GPER with the NO pathway, although suggested in previous studies (Broughton et al., 2010; Filice et al., 2009; Lindsey et al., 2011; Meyer et al., 2010), still need to be substantiated. Of note, although G-1-dependent vasodilation is endothelium-dependent, G-1 treatment of ovariectomized mRen2 Lewis rats alters neither aortic eNOS gene expression nor endothelium- and NO-dependent relaxation to acetylcholine (Lindsey et al., 2009), both of which unexpectedly remain intact despite severe hypertension and ovariectomy in this model. On the other hand, preliminary evidence indicates that GPER activation by G-1 and ICI 182,780 also evokes endothelium-independent coronary vasodilation by regulating potassium efflux via BKCa channels, possibly mediated by ERK and PI3K/Akt signaling pathways (Han et al., 2009, 2010).

Although there is now evidence that endothelium-derived NO is an important mediator of GPER-dependent vasodilation (Broughton et al., 2010; Lindsey et al., 2011; Meyer et al., 2010), it is unknown whether GPER activation also induces estrogen-dependent vasodilator responses through release of EDHFs, which has previously been shown for ERβ (Luksha et al., 2006; Traupe et al., 2007). EDHFs are important mediators of endothelium-dependent, NO-independent vasodilation in small resistance arteries, and estrogen therapy as well as a phytoestrogen-rich soy diet improve the EDHF response in mesenteric and uterine arteries of rodents (Burger et al., 2009; Knock et al., 2006). Based on the fact that G-1 dilates resistance arteries (Haas et al., 2009; Lindsey et al., 2011), it is plausible that GPER activation improves EDHF-dependent vasodilation in these small vessels, which may contribute to the observed blood pressure lowering effect of G-1 (Haas et al., 2009; Lindsey et al., 2009).

GPER may also reduce vascular tone by interfering with constrictor reactive oxygen species (ROS), since G-1 has antioxidative properties inhibiting ROS production (Broughton et al., 2010). Importantly, an excess amount of ROS impairs endothelial function mainly by reducing NO bioavailability (Ushio-Fukai, 2009). Moreover, ROS function as second messengers regulating signaling of G protein-coupled receptors such as the angiotensin II type 1 receptor, resulting in enhanced vasoconstriction (Ushio-Fukai, 2009). This may represent an additional mechanism whereby GPER beneficially affect vascular tone, particularly in the presence of impaired endothelial function due to cardiovascular diseases, such as hypertension or atherosclerosis.

In summary, current evidence suggests that ERα, ERβ, and GPER all contribute to estrogen-induced vasodilation, with a role for GPER best described in endothelium-/NO-dependent vasodilation. Selective GPER activation is also likely to induce NO-independent vasodilation and to reduce vascular tone via indirect effects on vasoconstrictors that are yet not fully understood. These responses depend on anatomical localization of vascular beds in different species and the time-course of estrogen administration. In line with its beneficial vasodilator effects, GPER also regulates cell growth and apoptosis of vascular smooth muscle cells (Ding et al., 2009; Haas et al., 2009), pointing towards a possible atheroprotective role of this receptor.

7. Protective effects of GPER on myocardial function

In view of the estrogen-dependent vasodilator effects and low incidence of coronary artery disease in premenopausal women (Meyer et al., 2006), a role for ER in protection from ischemic heart disease has been suggested (Deschamps et al., 2010). Endogenous estrogens convey protection in models of acute myocardial infarction and also have antiarrhythmic activity mimicking ischemic preconditioning, although the exact mechanisms involved are still unclear (Das and Sarkar, 2006; Deschamps et al., 2010). The ability of estrogen to stimulate NO generation has been of particular interest given that NO-dependent vasodilation may increase myocardial perfusion and thus contractility, alongside several other NO-mediated cardioprotective effects (Jones and Bolli, 2006). Of note, NO-mediated cholinergic vasodilation induced by coronary acetylcholine infusion is absent in patients with advanced coronary atherosclerosis, where infusion results in paradoxical vasoconstriction (Ludmer et al., 1986). In line with beneficial effects of estrogen on myocardial function, acute treatment with the non-selective ER agonist 17β-estradiol before temporary coronary artery occlusion reduces infarct size in female and male animals (Delyani et al., 1996; Hale et al., 1996, 1997). In addition, selective activation of ERβ provides cardioprotection that requires the availability of NO (Lin et al., 2009). Acute and chronic treatment of dogs or rodents with the SERM raloxifene also improves ischemia/reperfusion-related myocardial injury, and again partly involves NO-dependent mechanisms mediated by the PI3K/Akt-pathway (Chung et al., 2010; Nemcsik et al., 2004; Ogita et al., 2002, 2004). A number of experimental studies on ischemia/reperfusion injury subsequently found beneficial effects mediated by both ERα and ERβ, yet some controversies exist whether both receptors provide acute and chronic cardioprotection (Deschamps et al., 2010). Interestingly, functional crosstalk between ERα and ERβ determining the estrogen-dependent cardioprotective effects has also been suggested (Babiker et al., 2007).

Although these studies clearly demonstrate a role for both ERα and ERβ in cardiac pathophysiology, it is unclear whether effects are mediated by nuclear or membrane populations of these receptors. Also, several estrogen-dependent effects such as inhibition of cardiomyocyte cell growth and contraction involve mechanisms independent of ERα and ERβ (Mercier et al., 2003; Ullrich et al.,

Table 1  
GPER-mediated effects on cardiovascular function.

| Function                | Organ/tissue       | Species         | References                                                                 |
|-------------------------|--------------------|-----------------|---------------------------------------------------------------------------|
| Vasodilation            | Aorta              | Mouse           | (Haas et al., 2009)                                                       |
|                         |                    | Rat             | (Lindsey et al., 2009, 2011)                                              |
|                         | Carotid artery     | Mouse           | (Haas et al., 2009)                                                       |
|                         |                    | Rat             | (Broughton et al., 2010)                                                  |
|                         | Coronary artery    | Pig             | (Meyer et al., 2010)                                                      |
|                         | Mesenteric artery  | Rat             | (Haas et al., 2009; Lindsey et al., 2011)                                 |
|                         | Internal mammary   | Human           | (Haas et al., 2009)                                                       |
|                         | artery             |                 |                                                                         |
| Inhibition of           | Aorta              | Mouse           | (Haas et al., 2009)                                                       |
| vasoconstriction        |                    | Rat (OVX)       | (Lindsey et al., 2009)                                                    |
|                         | Carotid artery     | Mouse           | (Haas et al., 2009)                                                       |
|                         | Coronary artery    | Pig             | (Meyer et al., 2010)                                                      |
| Blood pressure          |                    |                 |                                                                         |
| Acute reduction         | Rat                |                 | (Haas et al., 2009)                                                       |
| Chronic                 | Rat (OVX)          |                 | (Lindsey et al., 2009)                                                    |
| reduction               |                    |                 |                                                                         |
| No chronic              | Rat                |                 | (Lindsey et al., 2009; Jessup et al., 2010)                               |
| effect                  | (Female)           |                 |                                                                         |
| Anti-ischemic           | Heart              | Mouse           | (Bopassa et al., 2010)                                                    |
| effects                 |                    | Rat             | (Deschamps and Murphy, 2009; Filice et al., 2009; Patel et al., 2010; Weil et al., 2010) |
|                         | Cardiomyocytes     | Mouse           | (Recchia et al., 2011)                                                    |
| Anti-inflammatory       | Heart              | Rat             | (Weil et al., 2010)                                                       |
| effects                 |                    |                 |                                                                         |
| Preservation of LV      | Heart              | Mouse           | (Delbeck et al., 2011)                                                    |
| structure/function      |                    | Rat             | (Jessup et al., 2010)                                                     |

LV, left-ventricular; OVX, ovariectomized.

2008). More recently, impaired left-ventricular contractility and relaxation capacity consistent with left-ventricular dysfunction were noted in male, but not in female GPER-deficient mice (Delbeck et al., 2011). G-1 ameliorates diastolic dysfunction and reduces left-ventricular hypertrophy in a model of salt-induced hypertensive cardiomyopathy independent of blood pressure (Jessup et al., 2010). In addition, involvement of estrogen signaling via GPER in ischemic heart disease has been suggested based on the observation of increased GPER expression mediated by hypoxia-inducible factor HIF-1α in a murine cardiomyocyte-like cell line in response to mimicking hypoxia (Recchia et al., 2011). These studies clearly indicate a role for GPER in preservation of cardiac structure and function (Table 1).

Using a model of cardiac ischemia/reperfusion injury, several groups reported additional GPER-dependent cardioprotective effects (Table 1). In rat hearts, G-1 treatment reduces infarct size and postischemic contractile dysfunction independent of sex (Fig. 4) (Deschamps and Murphy, 2009; Filice et al., 2009; Patel et al., 2010; Weil et al., 2010), possibly involving a PI3K kinase/Akt-dependent mechanism (Deschamps and Murphy, 2009). Similarly, the same treatment reduces infarct size and improves functional recovery in male mice by inhibiting the mitochondria permeability transition pore opening (Bopassa et al., 2010). In these animals, blocking of ERK signaling prevents the G-1-induced improvement in heart function

and infarct size (Bopassa et al., 2010). In rats, ERK activation by G-1 also mediates negative inotropic effects and induces the phosphorylation of eNOS (Filice et al., 2009), while no involvement of ERK signaling on acute cardioprotection was observed in a second report (Deschamps and Murphy, 2009). Interestingly, improved heart function in response to G-1 has been linked to a reduced production of proinflammatory cytokines including TNF-α, IL-1β, and IL-6 (Weil et al., 2010).

Taken together and consistent with its dilator effects, GPER activation improves functional recovery and infarct size after myocardial ischemia although the precise mechanisms mediating this protection remain to be characterized. Moreover, functional crosstalk between ERα, ERβ, and GPER may also determine the cardiac effects of estrogen as suggested by experimental studies using ICI 182,780 (Filice et al., 2009). In line with its beneficial effects on the heart, GPER may also be protective in scenarios involving acute hypoxic injury of other organs, such as ischemic stroke (Zhang et al., 2010) and liver injury (Hsieh et al., 2007).

## 8. Clinical implications and need for further research

Recent research has shown that GPER mediates numerous beneficial effects of estrogens on vascular and myocardial function. With the presence of three different cellular estrogen targets, predicting the cardiovascular response to estrogen has become increasingly complex due to nuclear and extranuclear localization and functional crosstalk between ERα, ERβ, and GPER, resulting in activation of multiple genomic and non-genomic signaling pathways (Fig. 1) (Meyer et al., 2009). Moreover, the identification of SERMs such as tamoxifen and raloxifene and SERDs such as ICI 182,780 as GPER agonists (Abdelhamid et al., 2011; Filardo et al., 2000; Revankar et al., 2005; Thomas et al., 2005) suggests that many previous studies using these compounds as “pure” agonists/antagonists of ERα and ERβ must be reconciled. Evidence for the role of GPER in the cardiovascular system is mainly based on studies using G-1 as a selective agonist. With the availability of GPER-knockout animals (Prossnitz and Barton, 2009) and the GPER antagonist G15 (Dennis et al., 2009), new experimental tools are available for more detailed mechanistic studies to better characterize the individual roles of GPER, ERα, and ERβ in the cardiovascular system (Meyer and Barton, 2009).

The complexity of estrogen signaling might in part also explain why clinical trials using conjugated equine estrogens and medroxyprogesterone acetate for postmenopausal hormone therapy failed to prove a therapeutic benefit on cardiovascular outcomes (Hulley et al., 1998; Rossouw et al., 2002). In addition, there were significant unfavorable effects mainly related to the development of breast cancer and venous thromboembolic events (Hulley et al., 1998; Rossouw et al., 2002). The scientific question therefore remains how to pharmacologically separate the beneficial vascular signaling pathways of estrogens from their harmful actions, which can possibly be achieved by tissue-specific, selective ER targeting devoid of the side effects seen with other estrogens. Interestingly, the SERMs raloxifene and lasofoxifene have recently been reported to reduce the risk of cardiovascular events and breast cancer at least in younger postmenopausal women (Barrett-Connor et al., 2006; Collins et al., 2009a; Cummings et al., 2010; Ensrud et al., 2010). On the other hand, raloxifene does not affect blood pressure of normo- and hypertensive postmenopausal women (Cagnacci et al., 2003; Collins et al., 2009; Morgante et al., 2006; Sumino et al., 2010). Compared to other SERMs currently available for postmenopausal women, lasofoxifene appears to have the most favorable cardiovascular benefit-to-risk profile, although it was primarily found to be effective when used for the treatment of osteoporosis and breast cancer (Ensrud et al., 2010). Therefore, randomized clinical trials using lasofoxifene in postmenopausal women who are at increased cardiovascular risk are warranted. This also indicates that the cardiovascular effects of distinct SERMs are
likely to differ. Thus, future basic research should further address the question how ERα, ERβ and GPER are involved in the cardiovascular effects observed after the treatment with different SERMs. In addition, designing synthetic ligands that selectively mimic the beneficial vascular effects of 17β-estradiol but lack its deleterious effects at pharmacological doses represents an exciting area of research ([Chow et al., 2010](https://doi.org/10.1210/en.2010-0865)). Based on the current evidence, G-1 might be a candidate for such a compound. In fact, with the accumulating evidence that GPER mediates a variety of beneficial cardiovascular effects, this receptor may represent a novel target to develop effective strategies to treat cardiovascular diseases based on the clear-cut evidence of beneficial effects of premenopausal estrogens on the cardiovascular system.

### Conflict of interest

E.R.P. is an inventor on United States Patent Number 7,875,721.

### Acknowledgments

Supported by Swiss National Science Foundation (SNSF) grants 3200-108528/1 and K-33KO-122504/1 (to M.B.) and PBZHP3-135874 (to M.R.M.), and National Institutes of Health (NIH) grants CA116662, CA118743 and CA127731 (to E.R.P.).

### References

Abdelhamid, R., Luo, J., VandeVrede, L., Kundu, I., Michalsen, B., Litosh, V.A., Schiefer, I.T., Gherezghiher, T., Yao, P., Qin, Z., Thatcher, G.R.J., 2011. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci. 18, 256–268.

Al Zubair, K., Razak, A., Bexis, S., Docherty, J.R., 2005. Relaxations to oestrogen receptor subtype selective agonists in rat and mouse arteries. Eur. J. Pharmacol. 513, 101–108.

Albanito, L., Madeo, A., Lappano, R., Vivacqua, A., Rago, V., Carpino, A., Oprea, T.I., Prossnitz, E.R., Musti, A.M., Ando, S., Maggiolini, M., 2007. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67, 1859–1866.

Alexander, S.P., Mathie, A., Peters, J.A., 2008. Guide to Receptors and Channels (GRAC), 3rd edition. Br. J. Pharmacol. 153 (Suppl 2), S1–S209.

Babiker, F.A., Lips, D.J., Delvaux, E., Zandberg, P., Janssen, B.J., Prinzen, F., van Eys, G., Grohe, C., Doevendans, P.A., 2007. Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol. (Oxf). 189, 23–31.

Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M.J., Grady, D., Kornitzer, M., McNabb, M.A., Wenger, N.K., 2006. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125–137.

Barton, M., Meyer, M.R., 2009. Postmenopausal hypertension: mechanisms and therapy. Hypertension 54, 11–18.

Barton, M., Cremer, J., Mügge, A., 1998. 17beta-estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur. J. Pharmacol. 362, 73–76.

Bolego, C., Cignarella, A., Sanvito, P., Pelosi, V., Pellegatta, F., Puglisi, L., Pinna, C., 2005. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-alpha agonists and is abolished by estrogen deprivation. J. Pharmacol. Exp. Ther. 313, 1203–1208.

Bologna, C.G., Revankar, C.M., Young, S.M., Edwards, B.S., Arterburn, J.B., Kiselyov, A.S., Parker, M.A., Tkachenko, S.E., Savchuck, N.P., Sklar, L.A., Oprea, T.I., Prossnitz, E.R., 2006. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2, 207–212.

Bopassa, J.C., Eghbali, M., Toro, L., Stefani, E., 2010. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 298, H16–H23.

Bracamonte, M.P., Jayachandran, M., Rud, K.S., Miller, V.M., 2002. Acute effects of 17beta-estradiol on femoral veins from adult gonadally intact and ovariectomized female pigs. Am. J. Physiol. Heart Circ. Physiol. 283, H2389–H2396.

Broughton, B.R., Miller, A.A., Sobey, C.G., 2010. Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. Am. J. Physiol. Heart Circ. Physiol. 298, H1055–H1061.

Burger, N.Z., Kuzina, O.Y., Osol, G., Gokina, N.I., 2009. Estrogen replacement enhances EDHF-mediated vasodilation of mesenteric and uterine resistance arteries: role of endothelial cell Ca²⁺. Am. J. Physiol. Endocrinol. Metab. 296, E503–E512.

Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., Horan, M.J., Labarthe, D., 1995. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25, 305–313.

Cagnacci, A., Zanni, A.L., Volpe, A., 2003. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am. J. Obstet. Gynecol. 188, 1278–1282.

Chambliss, K.L., Yuhanna, I.S., Mineo, C., Liu, P., German, Z., Sherman, T.S., Mendelsohn, M.E., Anderson, R.G., Shaul, P.W., 2000. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 87, E44–E52.

Chambliss, K.L., Yuhanna, I.S., Anderson, R.G., Mendelsohn, M.E., Shaul, P.W., 2002. ERbeta has nongenomic action in caveolae. Mol. Endocrinol. 16, 938–946.

Chambliss, K.L., Wu, Q., Oltmann, S., Konaniah, E.S., Umetani, M., Korach, K.S., Thomas, G.D., Mineo, C., Yuhanna, I.S., Kim, S.H., Madak-Erdogan, Z., Maggi, A., Dineen, S.P., Roland, C.L., Hui, D.Y., Brekken, R.A., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Shaul, P.W., 2010. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J. Clin. Invest. 120, 2319–2330.

Chan, Y.C., Leung, F.P., Wong, W.T., Tian, X.Y., Yung, L.M., Lau, C.W., Tsang, S.Y., Yao, X., Chen, Z.Y., Huang, Y., 2010. Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation. Arterioscler. Thromb. Vasc. Biol. 30, 992–999.

Chow, R.W., Handelsman, D.J., Ng, M.K., 2010. Minireview: rapid actions of sex steroids in the endothelium. Endocrinology 151, 2411–2422.

Chung, M.T., Cheng, P.Y., Lam, K.K., Chen, S.Y., Ting, Y.F., Yen, M.H., Lee, Y.M., 2010. Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats. Menopause 17, 127–134.

Collins, P., Mosca, L., Geiger, M.J., Grady, D., Kornitzer, M., Amewou-Atisso, M.G., Effron, M.B., Dowsett, S.A., Barrett-Connor, E., Wenger, N.K., 2009. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 119, 922–930.

Cruz, M.N., Douglas, G., Gustafsson, J.A., Poston, L., Kubliciene, K., 2006. Dilatory responses to estrogenic compounds in small femoral arteries of male and female estrogen receptor-beta knockout mice. Am. J. Physiol. Heart Circ. Physiol. 290, H823–H829.

Cummings, S.R., Ensrud, K., Delmas, P.D., LaCroix, A.Z., Vukicevic, S., Reid, D.M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., Armstrong, R.A., Thompson, D.D., Powles, T., Zanchetta, J., Kendler, D., Neven, P., Eastell, R., 2010. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 362, 686–696.

Darblade, B., Pendaries, C., Krust, A., Dupont, S., Fouque, M.J., Rami, J., Chambon, P., Bayard, F., Arnal, J.F., 2002. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ. Res. 90, 413–419.

Darkow, D.J., Lu, L., White, R.E., 1997. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am. J. Physiol. 272, H2765–H2773.

Das, B., Sarkar, C., 2006. Similarities between ischemic preconditioning and 17beta-estradiol mediated cardiomyocyte KATP channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart. J. Cardiovasc. Pharmacol. 47, 277–286.

Delbeck, M., Golz, S., Vonk, R., Janssen, W., Hucho, T., Isensee, J., Schäfer, S., Otto, C., 2011. Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol. Med. Rep. 4, 37–40.

Delyani, J.A., Murohara, T., Nossuli, T.O., Lefer, A.M., 1996. Protection from myocardial reperfusion injury by acute administration of 17 beta-estradiol. J. Mol. Cell. Cardiol. 28, 1001–1008.

Dennis, M.K., Burai, R., Ramesh, C., Petrie, W.K., Alcon, S.N., Nayak, T.K., Bologa, C.G., Leitao, A., Brailoiu, E., Deliu, E., Dun, N.J., Sklar, L.A., Hathaway, H.J., Arterburn, J.B., Oprea, T.I., Prossnitz, E.R., 2009. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 5, 421–427.

Deschamps, A.M., Murphy, E., 2009. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am. J. Physiol. Heart Circ. Physiol. 297, H1806–H1813.

Deschamps, A.M., Murphy, E., Sun, J., 2010. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med. 20, 73–78.

Ding, Q., Gros, R., Limbird, L.E., Chorazyczewski, J., Feldman, R.D., 2009. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR30. Am. J. Physiol. Cell. Physiol. 297, C1178–C1187.

Ensrud, K., LaCroix, A., Thompson, J.R., Thompson, D.D., Eastell, R., Reid, D.M., Vukicevic, S., Cauley, J., Barrett-Connor, E., Armstrong, R., Welty, F., Cummings, S., 2010. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 122, 1716–1724.

Figtree, G.A., Lu, Y., Webb, C.M., Collins, P., 1999. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100, 1095–1101.

Filardo, E.J., Quinn, J.A., Bland, K.I., Frackelton Jr., A.R., 2000. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14, 1649–1660.

Filice, E., Recchia, A.G., Pellegrino, D., Angelone, T., Maggiolini, M., Cerra, M.C., 2009. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J. Physiol. Pharmacol. 60, 3–10.

Furchgott, R.F., 1988. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that acid-activable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte, P.M. (Ed.), Vasodilation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium. Raven Press, New York, pp. 401–414.
Furchgott, R.F., Zawadzki, J.V., 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373–376.

Gao, F., Ma, X., Ostmann, A.B., Das, S.K., 2011. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology 152, 1434–1447.

Gisclard, V., Miller, V.M., Vanhoutte, P.M., 1988. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J. Pharmacol. Exp. Ther. 244, 19–22.

Gros, R., Ding, Q., Sklar, L.A., Prossnitz, E.R., Arterburn, J.B., Chorazyczewski, J., Feldman, R.D., 2011. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 57, 442–451.

Guo, X., Razandi, M., Pedram, A., Kassab, G., Levin, E.R., 2005. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J. Biol. Chem. 280, 19704–19710.

Haas, E., Meyer, M.R., Schurr, U., Bhattacharya, I., Minotti, R., Nguyen, H.H., Heigl, A., Lachat, M., Genoni, M., Barton, M., 2007. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 49, 1358–1363.

Haas, E., Bhattacharya, I., Brailoiu, E., Damjanovic, M., Brailoiu, G.C., Gao, X., Mueller-Guerre, L., Marjon, N.A., Gut, A., Minotti, R., Meyer, M.R., Amann, K., Ammann, E., Perez-Dominguez, A., Genoni, M., Clegg, D.J., Dun, N.J., Resta, T.C., Prossnitz, E.R., Barton, M., 2009. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 104, 288–291.

Hale, S.L., Birnbaum, Y., Klioner, R.A., 1996. Beta-estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. Am. Heart J. 132, 258–262.

Hale, S.L., Birnbaum, Y., Klioner, R.A., 1997. Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. J. Cardiovasc. Pharmacol. Ther. 2, 47–52.

Han, G., Ma, H., Chintala, R., Miyake, K., Fulton, D.J., Barman, S.A., White, R.E., 2007. Nongenomic, endothelium-independent effects of estrogen on human coronary smooth muscle are mediated by type I (neuronal) NOS and PI3-kinase-Akt signaling. Am. J. Physiol. Heart Circ. Physiol. 293, H314–H321.

Han, G., Barman, S.A., White, R.E., 2009. Rapid estrogen signaling via GPR30 in coronary artery smooth muscle. FASEB J. 23 (Meeting Abstract Supplement) abstract 968.5.

Han, G., Ma, H., Barman, S.A., Sellers, M., Yu, X., Stallone, J.N., White, R.E., 2010. Rapid estrogen signaling via GPER in human coronary artery smooth muscle. FASEB J. 24 (Meeting Abstract Supplement) abstract 957.1.

Harada, N., Sasano, H., Murakami, H., Ohkuma, T., Nagura, H., Takagi, Y., 1999. Localized expression of aromatase in human vascular tissues. Circ. Res. 84, 1285–1291.

Harrington, W.R., Sheng, S., Barnett, D.H., Petz, L.N., Katzenellenbogen, J.A., Katzenellenbogen, B.S., 2003. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell. Endocrinol. 206, 13–22.

Haynes, M.P., Sinha, D., Russell, K.S., Collinge, M., Fulton, D., Morales-Ruiz, M., Sessa, W.C., Bender, J.R., 2000. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res. 87, 677–682.

Hsieh, Y.C., Yu, H.P., Frink, M., Suzuki, T., Choudhry, M.A., Schwacha, M.G., Chaudry, I.H., 2007. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am. J. Pathol. 170, 1210–1218.

Hsieh, C.Y., Miaw, C.L., Hsieh, C.C., Tseng, H.C., Yang, Y.H., Yen, C.H., 2009. Effects of chronic 4-n-nonylphenol treatment on aortic vasoconstriction and vasorelaxation in rats. Arch. Toxicol. 83, 941–946.

Huang, A., Sun, D., Wu, Z., Yan, C., Carroll, M.A., Jiang, H., Falck, J.R., Kaley, G., 2004. Estrogen elicits cytochrome P450-mediated flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt phosphorylation in genomic regulation. Circ. Res. 94, 245–252.

Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280, 605–613.

Hutchison, S.J., Chou, T.M., Chatterjee, K., Sudhir, K., 2001. Tamoxifen is an acute, estrogen-like, coronary vasodilator of porcine coronary arteries in vitro. J. Cardiovasc. Pharmacol. 38, 657–665.

Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G., 1987. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 84, 9265–9269.

Isensee, J., Meoli, L., Zazzu, V., Nabzdyk, C., Witt, H., Soewarto, D., Effertz, K., Fuchs, H., Gailus-Durner, V., Busch, D., Adler, T., de Angelis, M.H., Irgang, M., Otto, C., Noppinger, P.R., 2009. Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology 150, 1722–1730.

Jacobs, M.N., Lewis, D.F., 2002. Steroid hormone receptors and dietary ligands: a selected review. Proc. Nutr. Soc. 61, 105–122.

Jessup, J.A., Lindsey, S.H., Wang, H., Chappell, M.C., Groban, L., 2010. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One 5 published online.

Jones, S.P., Bolli, R., 2006. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40, 16–23.

Katzenellenbogen, B.S., Katzenellenbogen, J.A., 2002. Defining the “S” in SERMs. Science 295, 2380–2381.

Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223.

Keung, W., Chan, M.L., Ho, E.Y., Vanhoutte, P.M., Man, R.Y., 2011. Non-genomic activation of adenylyl cyclase and protein kinase G by 17beta-estradiol in vascular smooth muscle of the rat superior mesenteric artery. Pharmacol. Res. published online.

Knock, G.A., Mahn, K., Mann, G.E., Ward, J.P., Aaronson, P.I., 2006. Dietary soy modulates endothelium-dependent relaxation in aged male rats: increased agonist-induced endothelium-derived hyperpolarising factor and basal nitric oxide activity. Free Radic. Biol. Med. 41, 731–739.

Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93, 5925–5930.

Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., Gustafsson, J.A., 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252–4263.

Leung, H.S., Yung, L.M., Leung, F.P., Yao, X., Chen, Z.Y., Ko, W.H., Laher, I., Huang, Y., 2006. Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms. Br. J. Pharmacol. 149, 703–711.

Leung, F.P., Yung, L.M., Leung, H.S., Au, C.L., Yao, X., Vanhoutte, P.M., Laher, I., Huang, Y., 2007a. Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilation in vitro. Br. J. Pharmacol. 152, 223–229.

Leung, H.S., Seto, S.W., Kwan, Y.W., Leung, F.P., Au, A.L., Yung, L.M., Yao, X., Huang, Y., 2007b. Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur. J. Pharmacol. 555, 178–184.

Lin, J., Steenbergen, C., Murphy, E., Sun, J., 2009. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 120, 245–254.

Lindsey, S.H., Cohen, J.A., Brosnihan, K.B., Gallagher, P.E., Chappell, M.C., 2009. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150, 3753–3758.

Lindsey, S.H., Carver, K.A., Prossnitz, E.R., Chappell, M.C., 2011. Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J. Cardiovasc. Pharmacol. 57, 598–603.

Ludmer, P.L., Selwyn, A.P., Shook, T.L., Wayne, R.R., Mudge, G.H., Alexander, R.W., Ganz, P., 1986. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046–1051.

Luksha, L., Poston, L., Gustafsson, J.A., Hultenby, K., Kubliciene, K., 2006. The estrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J. Physiol. 577, 945–955.

Ma, Y., Qiao, X., Falone, A.E., Reslan, O.M., Sheppard, S.J., Khalil, R.A., 2010. Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell. Physiol. Biochem. 26, 457–470.

Martensson, U.E., Salehi, S.A., Windahl, S., Gomez, M.F., Sward, K., Daszkiewicz-Nilsson, J., Wendt, A., Andersson, N., Hellstrand, P., Grande, P.O., Owman, C., Rosen, C.J., Adamo, M.L., Lundquist, I., Rorsman, P., Nilsson, B.O., Ohlsson, C., Olde, B., Leeblundberg, L.M., 2009. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150, 687–698.

Martin, D., Song, J., Mark, C., Eyster, K., 2008. Understanding the cardiovascular actions of soy isoflavones: potential novel targets for antihypertensive drug development. Cardiovasc. Hematol. Disord. Drug Targets 8, 297–312.

Matthews, J., Gustafsson, J.A., 2003. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 3, 281–292.

Mercier, I., Mader, S., Calderone, A., 2003. Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc. Res. 59, 883–892.

Meyer, M.R., Barton, M., 2009. ERalpha, ERbeta, and gpER: novel aspects of oestrogen receptor signalling in atherosclerosis. Cardiovasc. Res. 83, 605–610.

Meyer, M.R., Haas, E., Barton, M., 2006. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 47, 1019–1026.

Meyer, M.R., Haas, E., Prossnitz, E.R., Barton, M., 2009. Non-genomic regulation of vascular cell function and growth by estrogen. Mol. Cell. Endocrinol. 308, 9–16.

Meyer, M.R., Baretella, O., Prossnitz, E.R., Barton, M., 2010. Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 86, 58–64.

Miller, V.M., Duckles, S.P., 2008. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60, 210–241.

Morgante, G., Delia, A., Musacchio, M.C., Severi, F.M., Petraglia, F., De Leo, V., 2006. Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women. Gynecol. Endocrinol. 22, 376–380.

Mügge, A., Riedel, M., Barton, M., Kuhn, M., Lichtlen, P.R., 1993. Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc. Res. 27, 1939–1942.

Mügge, A., Barton, M., Fieguth, H.G., Riedel, M., 1997. Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17 beta-estradiol in human internal mammary arteries in vitro. Pharmacology 54, 162–168.

Nemcsik, J., Morschl, E., Egresits, J., Kordas, K., Laszlo, F., Laszlo, F.A., Pavo, I., 2004. Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo. Eur. J. Pharmacol. 495, 179–184.

Ogita, H., Node, K., Asanuma, H., Sanada, S., Liao, Y., Takashima, S., Asakura, M., Mori, H., Shinozaki, Y., Hori, M., Kitakaze, M., 2002. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J. Am. Coll. Cardiol. 40, 998–1005.

Ogita, H., Node, K., Asanuma, H., Sanada, S., Kim, J., Takashima, S., Minamino, T., Hori, M., Kitakaze, M., 2004. Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. 43, 821–829.

Patel, V.H., Chen, J., Ramanjaneya, M., Karteris, E., Zachariades, E., Thomas, P., Been, M., Randeva, H.S., 2010. G-protein coupled estrogen receptor 1 expression in rat and human heart: protective role during ischaemic stress. Int. J. Mol. Med. 26, 193–199.

Prossnitz, E.R., Barton, M., 2009. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat. 89, 89–97.

Recchia, A.G., De Francesco, E.M., Vivacqua, A., Sisci, D., Panno, M.L., Ando, S., Maggiolini, M., 2011. The G protein-coupled receptor 30 is up-regulated by hypoxia inducible factor-1{alpha} (HIF-1{alpha}) in breast cancer cells and cardiomyocytes. J. Biol. Chem. 286, 10773–10782.

Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., Prossnitz, E.R., 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625–1630.

Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C., Kotchen, J.M., Ockene, J., 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333.

Ruehlmann, D.O., Steinert, J.R., Valverde, M.A., Jacob, R., Mann, G.E., 1998. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca²⁺ channels in smooth muscle cells. FASEB J. 12, 613–619.

Scott, P.A., Tremblay, A., Brochu, M., St-Louis, J., 2007. Vasorelaxant action of 17-estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am. J. Physiol. Heart Circ. Physiol. 293, H3713–H3719.

Shanle, E.K., Xu, W., 2010. Selectively targeting estrogen receptors for cancer treatment. Adv. Drug Deliv. Rev. 62, 1265–1276.

Shaw, L., Taggart, M.J., Austin, C., 2000. Mechanisms of 17 beta-oestradiol induced vasodilation in isolated pressurized rat small arteries. Br. J. Pharmacol. 129, 555–565.

Silva de Sa, M.F., Meirelles, R.S., 1977. Vasodilating effect of estrogen on the human umbilical artery. Gynecol. Invest. 8, 307–313.

Simoncini, T., Hafezi-Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W., Liao, J.K., 2000. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538–541.

Simoncini, T., Genazzani, A.R., Liao, J.K., 2002. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105, 1368–1373.

Soloff, M.S., Szego, C.M., 1969. Purification of estradiol receptor from rat uterus and blockade of its estrogen-binding function by specific antibody. Biochem. Biophys. Res. Commun. 34, 141–147.

Sudhir, K., Chou, T.M., Mullen, W.L., Hausmann, D., Collins, P., Yock, P.G., Chatterjee, K., 1995. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J. Am. Coll. Cardiol. 26, 807–814.

Sumino, H., Ichikawa, S., Kasama, S., Takahashi, T., Kumakura, H., Takayama, Y., Kanda, T., Murakami, M., Kurabayashi, M., 2010. Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. Geriatr. Gerontol. Int. 10, 70–77.

Takada, Y., Kato, C., Kondo, S., Korenaga, R., Ando, J., 1997. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 240, 737–741.

Teoh, H., Leung, S.W., Man, R.Y., 1999. Short-term exposure to physiological levels of 17 beta-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc. Res. 42, 224–231.

Thomas, P., Dong, J., 2006. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid. Biochem. Mol. Biol. 102, 175–179.

Thomas, P., Pang, Y., Filardo, E.J., Dong, J., 2005. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146, 624–632.

Traupe, T., Stettler, C.D., Li, H., Haas, E., Bhattacharya, I., Minotti, R., Barton, M., 2007. Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 49, 1364–1370.

Ullrich, N.D., Krust, A., Collins, P., MacLeod, K.T., 2008. Genomic deletion of estrogen receptors ERAlpha and ERbeta does not alter estrogen-mediated inhibition of Ca²⁺ influx and contraction in murine cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 294, H2421–H2427.

Umetani, M., Domoto, H., Gormley, A.K., Yuhanna, I.S., Cummins, C.L., Javitt, N.B., Korach, K.S., Shaul, P.W., Mangelsdorf, D.J., 2007. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13, 1185–1192.

Ushio-Fukai, M., 2009. Vascular signaling through G protein-coupled receptors: new concepts. Curr. Opin. Nephrol. Hypertens. 18, 153–159.

Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'Donnell, C.J., Kannel, W.B., Levy, D., 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345, 1291–1297.

Vergote, I., Abram, P., 2006. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann. Oncol. 17, 200–204.

Weil, B.R., Manukyan, M.C., Herrmann, J.L., Wang, Y., Abbarbanell, A.M., Poynter, J.A., Meldrum, D.R., 2010. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 148, 436–443.

White, R.E., 2002. Estrogen and vascular function. Vascul. Pharmacol. 38, 73–80.

White, R.E., Darkow, D.J., Lang, J.L., 1995. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ. Res. 77, 936–942.

Zhang, B., Subramanian, S., Dziennis, S., Jia, J., Uchida, M., Akiyoshi, K., Migliati, E., Lewis, A.D., Vandenbark, A.A., Offner, H., Hurn, P.D., 2010. Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J. Immunol. 184, 4087–4094.

Zhu, Y., Bian, Z., Lu, P., Karas, R.H., Bao, L., Cox, D., Hodgkin, J., Shaul, P.W., Thoren, P., Smithies, O., Gustafsson, J.A., Mendelsohn, M.E., 2002. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295, 505–508.
